Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Ernest William Beckett (1856–1917), who became the 2nd Baron Grimthorpe. Helen Louisa Beckett-Denison (1858–1935). Adeline Gertrude Beckett-Denison (1859–1902), who married Sir Frederick Milner, 7th Baronet. Violet Katharine Beckett-Denison (1860–1883), who married Reginald Walkeline Chandos-Pole, grandson of Leicester Stanhope, 5th Earl of Harrington. Maud Augusta Beckett-Denison (1864–1927), who married Lord Henry Nevill (later 3rd Marquess of Abergavenny). William Gervase Beckett (1866–1937), who became Sir Gervase Beckett, 1st Baronet of Kirkdale Manor. Hon. Rupert Evelyn Beckett (1870–1955), who married Muriel Helen Florence Paget, granddaughter of Henry Paget, 2nd Marquess of Anglesey. Beckett died at the age of 64 when he fell under a train at Wimborne. He had arrived at Wimborne railway station to change trains for Bournemouth, and while waiting, he went for a walk. He was walking beside the track on the way back to the station when a strong wind blew his hat off, and he fell almost immediately under the train. His body was cut to pieces and carried some 56 feet. Following his death, Mrs. Gertrude Beatrice Brinkworth alleged she was his mistress and mother of his adopted children and sued his executors. Some money was paid, but the case came before the court, and the jury declared Mrs. Brinkworth's case to be a 'swindle' and rejected her claims even before the evidence in the case had been completed.
=== Dry fractionation method === The dry fractionation method is used to produce pea protein concentrates. It involves dry milling technology; a traditional mechanical process used to reduce the particle size of split or whole peas into coarse or fine flours. The outer shell of the pea is first dehulled, which is then milled via impact or jet milling to produce a flour. This process relies on differential particle size and density within the milled flour. Once milled, air classification is used, to separate the smaller protein-rich fragments from larger starch-rich granules or fibre-rich particles. During this process, an air flow fluidizes the milled flour in a separation chamber. A classifier wheel submerged in the bed selects the small particles and allows these to form the fine fraction. Larger particles are rejected by the classifier wheel, leave the chamber at the bottom, and make up the coarse fraction. Dry fractionation is a more sustainable method of processing as it does not require the use of water and energy is not required to dry the protein.
== Applications == Orbitrap-based mass spectrometers are used in proteomics and are also used in life science mass spectrometry such as metabolism, metabolomics, environmental, food and safety analysis. Most of them are interfaced to liquid chromatography separations, though they are also used with gas chromatography, secondary ion and ambient ionization methods. Orbitrap mass spectrometers have also been used to determine bulk and position-specific isotope ratios at natural abundance.
=== 1994 === 28 August For Whom the Road Tolls, about road charging; the M25-M23 Merstham junction; Anthony Pratt of Peek; Brian Harbord of the Highways Agency; George Giannapoulos of the University of Thessalonika; Stuart Cole of the University of North London; the Rebecca riots in 1843 in Wales; railways stopped turnpikes; there were 25 million cars on UK roads; Edmund King of the RAC; motorways could hold two thousand cars per lane per hour, at the most; Cologne Cathedral; the A555 between Cologne and Bonn, on a GPS electronic tolling experiment; Uwe Pertz of DeTe Mobil; Adept at Newcastle University, run by Saab, Peek and the EU, tested in Greece; the A167(M) and the Robinson Library; Philip Blythe of Newcastle University; Greece had 25 toll sites on its motorways; Trondheim in Norway had an electronic toll system since 1991, with total enforcement; Gunnar Frederiksen of Trolag; Peter Enter of Siemens, and an early version of ANPR; Chris Leithead of the Metropolitan Police; the M6 in Lunedale in Cumbria; 15% of traffic in the UK was on motorways, with an average of 5,000 miles per year per driver; Godstone traffic control centre in Surrey; individual rogue motorists could cause hold ups.
Sources: en.wikipedia.org
Eteplirsen (brand name Exondys 51) is a medication to treat, but not cure, some types of Duchenne muscular dystrophy (DMD), caused by a specific mutation. Eteplirsen only targets specific mutations and can be used to treat about 14% of DMD cases. Eteplirsen is a form of antisense therapy. Eteplirsen was developed by Steve Wilton, Sue Fletcher and colleagues at the University of Western Australia and commercialized by Sarepta Therapeutics. After a controversial debate surrounding the drug's efficacy, during which two FDA review panel members resigned in protest, eteplirsen received accelerated approval from the US Food and Drug administration in late 2016. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) refused to authorize the use of eteplirsen.
Actinobacteria are also halophilic psyschrophiles that have been found in brine pockets, known for their ability to produce a wide range of secondary metabolites, including antibiotics and other bioactive compounds. Actinobacteria are often found in association with other microorganisms, where they may play a role in protecting their host from pathogens or other threats. Lastly, bacteroidetes are found to be abundant in brine pockets, as they can degrade complex organic matter, including carbohydrates and proteins, such as algae-derived ocean polysaccharides. Compared to other bacteria, bacteroidetes species have been shown to contain more genes associated with polysaccharide degradation, allowing them to play a major contributing role in brine pocket carbon- and nutrient-cycling.
"Cellulose" . Encyclopædia Britannica. Vol. 5 (11th ed.). 1911. Structure and morphology of cellulose by Serge Pérez and William Mackie, CERMAV-CNRS Cellulose, by Martin Chaplin, London South Bank University Clear description of a cellulose assay method at the Cotton Fiber Biosciences unit of the USDA. Cellulose films could provide flapping wings and cheap artificial muscles for robots – TechnologyReview.com
=== Treatment === An antidote has been developed by the British Armed Forces, although as of 2006, it has not yet been tested on humans. As of 2005, another antidote developed by the US military has been shown to be safe and effective in lab mice injected with antibody-rich blood mixed with ricin, and has had some human testing. Monoclonal antibodies are under scientific investigation as a possible treatment for ricin poisoning. Symptomatic and supportive treatments are available for ricin poisoning. Existing treatments emphasize minimizing the effects of the poison. Possible treatments include intravenous fluids or electrolytes, airway management, assisted ventilation, or giving medications to remedy seizures and low blood pressure. If the ricin has been ingested recently, the stomach can be flushed by ingesting activated charcoal or by performing gastric lavage. Survivors often develop long-term organ damage.
Commonly used for multilayer coating in the photographic industry. Slot die bead coating – typically with the web backed by a roller and a very small gap between slot-die and web. Tensioned-web slot-die coating – with no backing for the web. Inkjet printing Lithography Flexography
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.